AmritaGen’s Cap-Exosomes Mediated Drug Delivery to the brain.
Systemic delivery of Cap-exosomes loaded with specific genes and/or FDA-approved drug molecules will have the potential, unlike other sAD therapies currently under developments to rebuild brain circuits and stimulate neuro-glia-vascular synchronized activity that is impaired in patients with mild cognitive impairments (MCI) and sAD patients.